John Harsh, CHEST 2022: Long term safety of FT218 in the treatment of narcolepsy

Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study.

The abstract ‘LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE.’ (Poster 2111) was presented at CHEST 2022, 16-19 October, 2022.

Questions

1. ​​What challenges are associated with the use of sodium oxybate in the treatment of narcolepsy? (0:24)
2. What is FT218? (1:20)
3. What are the aims, design and inclusion criteria of the RESTORE study? (2:01)
4. What have been the interim findings among people who switched from twice nightly sodium oxybate to FT218? (2:31)
5. If approved, what will be the clinical impact of FT218? (3:18)

Disclosures: John Harsh has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the CHEST meeting 2022.